Statistics
Total Visits
Views | |
---|---|
A Phase I Study of GSK2816126, an Enhancer of Zeste Homolog 2(EZH2) Inhibitor, in Patients (pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Other Non-Hodgkin Lymphomas (NHL), Transformed Follicular Lymphoma (tFL), Solid Tumors and Multiple Myeloma (MM) | 130 |
Total Visits Per Month
March 2024 | April 2024 | May 2024 | June 2024 | July 2024 | August 2024 | September 2024 | |
---|---|---|---|---|---|---|---|
A Phase I Study of GSK2816126, an Enhancer of Zeste Homolog 2(EZH2) Inhibitor, in Patients (pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Other Non-Hodgkin Lymphomas (NHL), Transformed Follicular Lymphoma (tFL), Solid Tumors and Multiple Myeloma (MM) | 2 | 0 | 1 | 0 | 2 | 9 | 1 |
Top country views
Views | |
---|---|
Poland | 62 |
United States | 21 |
Cyprus | 10 |
China | 5 |
Ireland | 3 |
France | 2 |
Greece | 2 |
India | 2 |
Argentina | 1 |
Australia | 1 |
Top cities views
Views | |
---|---|
Warsaw | 62 |
Limassol | 10 |
San Ramon | 6 |
Beijing | 4 |
Dublin | 3 |
Menlo Park | 3 |
San Mateo | 3 |
Athens | 2 |
Delhi | 2 |
Des Moines | 2 |